Evaluation of oncoReveal Essential MPN Panel on Illumina MiSeq i100 for Key Driver Mutation Testing in Myeloproliferative Neoplasms
Mayo Clinic’s Molecular Hematopathology Laboratory evaluated Pillar’s oncoReveal® Essential MPN Panel — a single-tube SLIMamp® amplicon NGS assay targeting JAK2, CALR, and MPL — on the Illumina MiSeq i100 for BCR::ABL1-negative myeloproliferative neoplasm (MPN) testing. Ninety-four peripheral blood and bone marrow specimens were compared against the laboratory’s capture-based myeloid NGS panel, JAK2 V617F allele-specific PCR, CALR fragment analysis, and MPL Sanger sequencing. The panel showed 91–100% concordance across comparators and returned results within 24 hours of extraction, against 5–7 days for the conventional reflex cascade.
Analytical Concordance of NGS-based Tests for ESR1 Mutation Detection in Plasma
